A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Trial Profile

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Arsenic trioxide (Primary)
  • Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Acute promyelocytic leukaemia; Haematological disorders; Mantle-cell lymphoma; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Orsenix
  • Most Recent Events

    • 17 Jun 2018 Results (n=7) presented at the 23rd Congress of the European Haematology Association
    • 08 Dec 2017 Planned number of patients changed from 50 to 20.
    • 15 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top